CEO Total Pay
$297K
FY2024 Summary Compensation, below median
RNA FY2024 SEC EDGAR DEF 14A
Avidity Biosciences, Inc. CEO pay ratio
The CEO earned $297K in FY2024 against median worker pay of $297,345 · Chemicals & Pharmaceuticals.
- State
- DE
- Filing date
- 2025-04-29
- Industry
- Chemicals & Pharmaceuticals
- Fiscal year
- FY2024
Data updated August 2026
Subscribe to Avidity Biosciences, Inc. CEO pay filing updates (RSS)
CEO-to-worker pay ratio
48:1
Below Average (Scale: 0–1000:1)
CEO pay
$297K
Median worker
$297,345
Latest filing FY2024. This company's newest DEF 14A on file is for FY2024, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.
Answer first
Avidity Biosciences, Inc. reported a 48:1 CEO-to-worker pay ratio in FY2024 - above the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.
Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
- Pay ratio
- 48:1
- FY2024 disclosed
- CEO total
- $297K
- Summary Compensation Table total
- Median worker
- $297,345
- Dodd-Frank median employee
Ratio bands among Chemicals & Pharmaceuticals peers
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
CEO Compensation Breakdown, FY2024
A component-level pay breakdown is not reported in Avidity Biosciences, Inc.'s structured SEC pay-ratio disclosure. See our methodology →
Filing-year trail · Avidity Biosciences, Inc.
Complete DEF 14A pay-ratio filings for this CIK across FY2022–2024. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).
- Latest ratio
- 48:1
- FY2024
- vs prior FY
- -2:1
- from FY2023 50:1
- CEO $ YoY
- +32%
- $297K latest
- Filings shown
- 3
- FY2022–2024
| FY | CEO pay | Δ pay | Median worker | Pay ratio | Δ ratio |
|---|---|---|---|---|---|
| 2022 | $257K | - | $256,916 | 21:1 | - |
| 2023 | $225K | -13% | $224,701 | 50:1 | +29:1 |
| 2024 | $297K | +32% | $297,345 | 48:1 | -2:1 |
Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1599901, FY2022–2024. Adjacent-year deltas only.
Industry Comparison - Chemicals & Pharmaceuticals
This Company's Ratio
48:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$297K
Companies in Industry
168
vs. Industry Median
Above
Avidity Biosciences, Inc.: MODEST · MICRO pay ratio
Avidity Biosciences, Inc. disclosed 48:1 CEO-to-worker pay and $297K CEO total in FY2024. the CEO earned 48× the median employee ($297,345) in FY2024.
Median employee $297,345 (ELITE-MED); MODEST · MICRO stamps put about 48 median-wage years per CEO year.
Pay Ratio
48:1
Below typical
What FY2024 shows for Avidity Biosciences, Inc.
Avidity Biosciences, Inc. disclosed 48:1 CEO-to-worker pay and $297K CEO total in FY2024. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Avidity Biosciences, Inc.'s $297K CEO total is at or below the $7.9M industry median CEO pay.
Avidity Biosciences, Inc. stamps MODEST · MICRO · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.
Key Data, FY2024
- Total Compensation
- $297K
- Median Employee Pay
- $297,345
- Pay Ratio
- 48:1
- Filing Date
- 2025-04-29
Company Info
- Ticker
- RNA
- CIK
- 1599901
- Industry
- Chemicals & Pharmaceuticals
- SIC Code
- 2834
- State
- DE
SEC EDGAR DEF 14A for CIK 1599901, FY2024. Informational only, not investment advice. Verify on EDGAR.
Read our methodology - how this data is sourced, computed, and verified. Avidity Biosciences, Inc. disclosed 48:1 CEO-to-worker pay and $297K CEO total in FY2024.
Read with Avidity Biosciences, Inc.
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · MICRO · ELITE-MED.
Snowflake Inc. · MICRO
ABS(ceo_total_comp) peer at $298K (Δ $874 heavier vs Avidity Biosciences, Inc.); HIGH · ELITE-MED vs this page's MODEST · MICRO · ELITE-MED.
Capital Southwest Corp · MICRO
ABS(ceo_total_comp) peer at $301K (Δ $4K heavier vs Avidity Biosciences, Inc.); FLOOR · ELITE-MED vs this page's MODEST · MICRO · ELITE-MED.
Arvinas, Inc. · MICRO
ABS(ceo_total_comp) peer at $293K (Δ $5K lighter vs Avidity Biosciences, Inc.); MODEST · ELITE-MED vs this page's MODEST · MICRO · ELITE-MED.
Rpc Inc · MICRO
ABS(ceo_total_comp) peer at $303K (Δ $6K heavier vs Avidity Biosciences, Inc.); FLOOR · HIGH-MED vs this page's MODEST · MICRO · ELITE-MED.
Chemicals & Pharmaceuticals benchmark
Avidity Biosciences, Inc. stamps MODEST · MICRO · ELITE-MED inside SIC 28 - open the industry median board after the ABS peers.
Pay-ratio rankings · MODEST
See where MODEST · MICRO packages sit on the national leaderboard after reading Avidity Biosciences, Inc..
Ratio primer · MODEST
Avidity Biosciences, Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Avidity Biosciences, Inc. (CIK 1599901), FY2024. See our methodology. Aggregated by PlainCEOPay as of August 2026.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.